Recent Updates
Recently added Catalysts
RGNX Positive Sentiment Score: 75/100

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference

Monday, February 6, 2023 2 min read
Key Takeaway: REGENXBIO Inc. has announced three upcoming presentations related to RGX-314 at the Angiogenesis, Exudation, and Degeneration 2023 Conference. The conference will feature findings from a Phase II bridging study assessing the drug's pharmacodynamics, safety, and efficacy. These presentations aim to showcase advancements in gene therapy, particularly for conditions like neovascular age-related macular degeneration and diabetic retinopathy. The event will take place virtually from February 10-11, 2023.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentations at a prominent conference highlight RGX-314's development.
  • New data from a Phase II study could support future commercialization.
  • REGENXBIO's commitment to advancing gene therapy is evident.

Full Press Release Details

ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three presentations on RGX-314 will be presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference taking place virtually from February 10-11, 2023. New data will be presented from a Phase II bridging study evaluating the pharmacodynamics, safety and efficacy of RGX-314 delivered subretinally using cGMP material produced by the REGENXBIO NAVXpress™ platform process to support future commercialization.
The presentations will be as follows:
Presentation Title: Subretinal Delivery of RGX-314 for Neovascular AMD: A Phase II Pharmacodynamic Study
Presenter: Charles C. Wykoff, M.D., PhD, Retina Consultants of Texas
Date/Time: Saturday, February 11, 2023, 8:40 a.m. ET
Presentation Title: Long-Term Follow-Up of Durable Subretinal RGX-314 Gene Therapy for Exudative AMD
Presenter: Allen C. Ho, M.D., Director of Retina Research, Wills Eye Hospital, Mid Atlantic Retina
Date/Time: Saturday, February 11, 2023, 8:50 a.m. ET
Presentation Title: Suprachoroidal Therapy for Diabetic Retinopathy
Presenter: Peter A. Campochiaro, M.D., Director, Retinal Cell and Molecular Laboratory
Professor of Ophthalmology, John Hopkins School of Medicine
Date/Time: Saturday, February 11, 2023, 10:40 a.m. ET
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5 x '25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Corporate Communications
SOURCE REGENXBIO Inc.

21 %

more press release views with

Frequently Asked Questions

What is RGX-314?

RGX-314 is a gene therapy designed for treating eye diseases such as neovascular AMD.

When will the RGX-314 presentations occur?

The presentations on RGX-314 are scheduled for February 11, 2023.

Who is presenting the RGX-314 data?

Presenters include Charles C. Wykoff, Allen C. Ho, and Peter A. Campochiaro.

What platform is used to produce RGX-314?

RGX-314 is produced using REGENXBIO's NAVXpress™ platform.

What is REGENXBIO's goal by 2025?

REGENXBIO aims to advance five AAV Therapeutics to pivotal-stage or commercialization.

Tags: RGNX Viatris Investor Conferences Healthcare REGENXBIO gene therapy Phase II study Angiogenesis Conference
Last updated: Feb 6, 2023